Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 IN PLASTIC CONTAINER versus AMINOSYN PF 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 IN PLASTIC CONTAINER versus AMINOSYN PF 10.
AMINOSYN 3.5% IN PLASTIC CONTAINER vs AMINOSYN-PF 10%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosin 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair and growth in patients unable to tolerate oral/enteral nutrition.
Aminosyn-PF 10% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in neonates and pediatric patients.
Intravenous infusion of 500 mL to 1 L daily, providing 3.5% amino acids (31.5 g protein per liter). Administer at a rate not exceeding 100 mL/hour initially, adjusted based on metabolic tolerance.
Intravenous infusion: 1-1.5 g amino acids/kg/day (protein equivalent) as part of total parenteral nutrition. Typical rate: 0.5-2.0 mL/kg/hour initially, titrated to metabolic needs.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is approximately 18-24 minutes, reflecting rapid clearance from plasma into tissues for protein synthesis.
Variable; amino acids have half-lives of minutes to hours; clinical context: continuous infusion maintains steady state
Amino acids are metabolized to urea and carbon dioxide; urea is excreted renally (90%) and to a lesser extent via sweat and feces (<10%).
Renal: >90% as amino acids and metabolites; <10% fecal/biliary
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution